Income Statement
AMYLYX PHARMACEUTICALS, INC.
AMLX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Revenue
|
0.00 | 87.37 | 380.79 | 22.23 |
|
Cost of Revenue
|
0.00 | 124.63 | 25.44 | 2.99 |
|
Gross Profit
|
- | -37.26 | 355.35 | 19.24 |
|
Operating Expenses
|
153.29 | 218.42 | 316.54 | 220.58 |
|
Research & Development
|
90.40 | 104.08 | 128.19 | 93.45 |
|
Selling, General & Administrative
|
62.89 | 114.33 | 188.36 | 127.13 |
|
Other Operating Expenses
|
- | - | - | - |
|
Operating Income
|
-153.29 | -255.68 | 38.80 | -201.34 |
|
Non-Operating Income
|
8.60 | 12.60 | 15.50 | 3.74 |
|
Interest Income
|
9.30 | 13.81 | 16.16 | 4.29 |
|
Interest Expense
|
- | - | - | - |
|
Other Non-Op Income / Expense
|
-0.70 | -1.21 | -0.66 | -0.55 |
|
Income Before Tax
|
-144.69 | -302.14 | 54.30 | -197.60 |
|
Income Tax Expense
|
0.05 | -0.39 | 5.03 | 0.77 |
|
Non-Controlling Interest
|
- | - | - | - |
|
Net Income
|
-144.74 | -301.74 | 49.27 | -198.38 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - |
|
EBITDA
|
-153.29 | -255.68 | 38.80 | -201.34 |
|
Earnings Per Share (Basic)
|
-1.53 | -4.43 | 0.73 | -3.39 |
|
Diluted EPS
|
-1.53 | -4.43 | 0.70 | -3.39 |
|
Weighted Average Shares
|
94.57 | 68.14 | 67.23 | 58.50 |
|
Diluted Weighted Avg Shares
|
94.57 | 68.14 | 69.99 | 58.50 |
|
Comprehensive Income
|
-144.24 | -302.03 | 49.55 | -198.47 |